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Prevention of Thromboembolic
Events After Bioprosthetic
Aortic Valve Replacement
What Is the Optimal
Antithrombotic Strategy?*
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John W. Eikelboom, MBBS,‡
Hamilton, Ontario, Canada
Valvular heart disease affects more than 100 million people
worldwide and is a growing problem because of the high
incidence of rheumatic heart disease in developing countries
and the increasing burden of degenerative valve disease in
the aging world population (1). Replacement of the diseased
valve by a mechanical or biological prosthesis remains the
only definitive treatment for valvular heart disease and is
performed in several hundred thousand patients each year
(2). Because they are much more durable than bioprosthe-
ses, mechanical valve replacements are preferred in younger
patients, but the disadvantage is that these mechanical
replacements require lifelong treatment with a vitamin K
antagonist, which necessitates lifestyle restrictions and rou-
tine coagulation monitoring. Consequently, older patients
requiring valve replacement surgery usually elect to receive a
bioprosthesis.
See page 971
An important unresolved issue in patients undergoing
bioprosthetic heart valve replacement concerns the optimal
initial antithrombotic treatment. Although less thrombo-
genic than mechanical valves, bioprostheses appear to be
moderately prothrombotic during the first 3 months after
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GlaxoSmithKline, and Sanofi-Aventis.surgery, presumably because they have a smaller effective
orifice area than native valves do, which creates a transval-
vular flow gradient, and they are not yet fully endothelial-
ized (3). Observational studies suggest that bioprosthetic
valves have a 1% to 5% annual risk of thromboembolic
complications, even with the routine use of early antithrom-
botic prophylaxis, but studies are small and contemporary
data are lacking (4,5). Two pilot randomized controlled
trials have compared anticoagulation with antiplatelet ther-
apy in patients with bioprosthetic valves, but collectively
they involved less than 300 patients and their results were
inconclusive (6,7).
Uncertainty about the efficacy and safety of anticoagulants
compared with antiplatelet drugs for prevention of thrombo-
embolic events during the first 3 months after bioprosthetic
heart valve replacement is reflected by contrasting recommen-
dations of international guidelines (Table 1) and highly
variable physician practices (8). The European Society of
Cardiology guidelines recommend warfarin (international
normalized ratio: 2.0 to 3.0), although they do not grade the
strength of this recommendation or the quality of evidence
on which it is based (9). The American College of Cardi-
ology/American Heart Association strongly recommend
aspirin and provide a weaker recommendation for warfarin.
The exception is patients deemed to be at high risk for
thromboembolic complications (atrial fibrillation, left ven-
tricular dysfunction, previous thromboembolism, and hy-
percoagulable condition) for whom they strongly recom-
mend warfarin (10). The American College of Chest
Physicians’ guidelines recommend aspirin over warfarin
(except for patients with atrial fibrillation), but this is a weak
recommendation based on low-quality evidence (11).
In this issue of the Journal, Brennan et al. (12) report rates
of readmission for thromboembolic and bleeding events
between the time of hospital discharge and 3 months of
follow-up in 25,656 patients at least 65 years of age
undergoing bioprosthetic aortic valve replacement who were
discharged home on aspirin, warfarin, or the combination of
aspirin and warfarin. The investigators identified patients
undergoing bioprosthetic aortic valve replacement using the
Society of Thoracic Surgeons’ database, which contains data
on patients undergoing cardiac surgery at 797 hospitals in
the United States, and used propensity methods to adjust
for confounding due to differences in baseline characteristics
between patients who received an anticoagulant and those
who were treated with antiplatelet therapy.
The major findings of the study of Brennan et al. (12) can
be summarized as follows.
First, there was substantial variation in the choice of
antithrombotic therapy during the first 3 months after
surgery for a bioprosthetic aortic valve replacement. War-
farin was more commonly used in patients with concomi-
tant atrial fibrillation, but less than 60% of patients who
received warfarin had atrial fibrillation.
rial fibr
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first 3 months was remarkably low, ranging from 0.6% in
patients who received the combination of aspirin and
warfarin to 1.0% in those who received either aspirin alone
or warfarin alone. Although this excluded early in-hospital
events, the low event rates in patients treated with aspirin
alone are reassuring and suggest that the routine use of
warfarin following bioprosthetic aortic valve replacement is
unnecessary. The low event rates also indicate that any
future randomized controlled trial comparing different an-
tithrombotic strategies following bioprosthetic aortic valve
replacement will require many thousands of patients.
Third, there was no advantage of warfarin over aspirin for
the prevention of thromboembolic events (adjusted risk ratio
[RR]: 0.95, 95% confidence interval [CI]: 0.61 to 1.47) but
also no increase in bleeding (adjusted RR: 1.23, 95% CI:
0.85 to 1.79). This latter finding contradicts many studies
demonstrating higher risks of bleeding with warfarin com-
pared with aspirin and might be explained by exclusion of
patients with a contraindication for warfarin because of
post-operative anticoagulant complication or gastrointesti-
nal complications in hospital.
Fourth, the combination of aspirin and warfarin com-
pared with aspirin alone reduced death by 20% (adjusted
RR: 0.80, 95% CI: 0.66 to 0.96) and thromboembolic
events by 48% (adjusted RR: 0.52, 95% CI: 0.35 to 0.76), at
the cost of a 2.8-fold increase in bleeding (adjusted RR:
2.80, 95% CI: 2.18 to 3.60). The mortality effect became
evident only after propensity adjustment, and the investiga-
tors do not report whether the benefits of the combination
of aspirin and warfarin over aspirin was driven by patients
with atrial fibrillation. The reduction in mortality is unex-
pected because the absolute reduction in thromboembolic
events (0.4%) was outweighed by a much greater absolute
increase in bleeding events (1.8%) and both thromboem-
bolic and bleeding events were associated with a similar (3%
to 4%) case-fatality at 2 weeks. Thus, it appears that the
effects of the combination of aspirin and warfarin compared
with aspirin on risk of thromboembolism and bleeding
cannot explain the 20% mortality reduction.
The main strengths of the study by Brennan et al. (12) are
that it included large numbers of consecutive, unselected
patients undergoing bioprosthetic aortic valve replacement
Comparison of Current ACC/AHA, ACCP, and ESC Guideline RecomAntithrombotic Therapy During the First 3 Months in Patients WithTable 1 Compa ison of Current A C/AHA, A CP, and ESC GuidAntithrombotic Therapy During the First 3 Months in P
Bioprosthesis ACC/AHA
AVR, low risk (sinus rhythm) ASA 75–100 mg/day (Class I*)
Warfarin INR: 2.0–3.0 (Class IIa†)
AVR, high risk§ ASA 75–100 mg/day (Class I*)
Warfarin INR: 2.0–3.0 (Class I*)
*Class I: conditions for which there is evidence for and/or general agreement that the procedur
usefulness/efficacy. ‡Grade 2c: weak recommendation based on low quality of evidence. §AHA ris
condition; ACCP risk factors: atrial fibrillation.
ACC American College of Cardiology; ACCP American College of Chest Physicians; AF at
eplacement; ESC  European Society of Cardiology; INR  international normalized ratio; VKA who were followed during the period of highest risk forthromboembolic and bleeding events. The main limitations
are that it did not count pre-discharge in-hospital throm-
boembolic and bleeding events or post-discharge out-of-
hospital events that did not prompt readmission and cannot
exclude the potential for confounding despite careful pro-
pensity adjustment.
What are the implications of these results for clinical
practice? The data by Brennan et al. (12) suggest that for the
majority of patients undergoing aortic bioprosthetic valve
replacement, aspirin alone provides adequate protection against
thromboembolic complications during the first 3 months after
discharge from hospital. Warfarin alone does not appear to
offer any benefits over aspirin in unselected patients, but the
combination of warfarin and aspirin may reduce thromboem-
bolic events and seems to be a reasonable option in patients
who are at increased risk of thromboembolic events because
they have atrial fibrillation. Despite the data suggesting a
reduction in thromboembolic events with warfarin plus aspirin,
we do not recommend the combination in all patients because
the data are not of high quality; questions remain about the
apparent reduction in mortality; and there is a large body of
high-quality evidence that the combination increases bleeding.
Our recommendation concerning the choice of antithrombotic
therapy applies to patients at the time of discharge from
hospital who do not have a contraindication to warfarin and
should also take into account patient values and preferences
concerning the balance between thromboembolic and bleeding
risks.
What are the implications of these results for future itera-
tions of antithrombotic guidelines? Although the data by
Brennan are observational, we believe that they represent the
highest quality evidence available for early antithrombotic
management of patients undergoing bioprosthetic aortic valve
replacement and thus should influence guideline recommen-
dations. Based on the very low rates of thromboembolic events
in this study, randomized trials to test different antithrombotic
strategies in this population are unlikely ever to be performed
and thus the study by Brennan et al. will likely remain the best
guide for many years to come.
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